The Affordable Care Act’s changes in payment and reduction in benchmarks in Medicare Advantage raised questions about the future of the program that ended up being unfounded, said Sean Cavanaugh, deputy administrator and director of the Center for Medicare at CMS, during the opening keynote at America’s Health Insurance Plans’ National Conference on Medicare, held October 24-25 in Washington, DC.
The Affordable Care Act (ACA)’s changes in payment and reduction in benchmarks in Medicare Advantage (MA) raised questions about the future of the program that ended up being unfounded, said Sean Cavanaugh, deputy administrator and director of the Center for Medicare at CMS, during the opening keynote at America’s Health Insurance Plans’ National Conference on Medicare, held October 24-25 in Washington, DC.
The MA program has seen significant enrollment growth so that it now covers 32% of all Medicare beneficiaries. In fact, the MA program has been growing much faster than the Medicare program itself, Cavanaugh said.
Another concern had been the effect the ACA would have on premiums. Cavanaugh showed that premiums are actually down from the pre-ACA days and have been remarkably stable over the period of time since the implementation of the law. In fact, the forecast for 2017 calls for a slight reduction (-4%) in premiums, which would be the second year in a row of premium reductions.
Plus, access to the MS program remains strong. While the number of counties without access to an MA plan will go up next year, they will be less populated counties, so the percentage of Medicare beneficiaries without access to an MA plan will remain largely unchanged.
With such strong growth in MA enrollment and premiums going down year over year, it was important to determine that quality of care remained high, Cavanaugh said. In 2009, just 17% of beneficiaries were in MA plans that had received 4 or 5 stars in the Medicare quality program. In comparison, 71% of beneficiaries in 2016 were in plans with 4 or 5 stars.
The forecast for 2017 predicts a slight decline to 68% of beneficiaries in 4- or 5-star plans, but there are a number of sizable plans contesting their 2017 ratings. Still, it's important to keep on eye on this trend to determine if the decline for 2017 is a blip and the upward trend will resume in 2018, or if the program is plateauing, Cavanaugh said.
However, it’s not all good news for the MA program. The Part D premium is going up slightly in 2017.
“While we have successfully held down premiums, I think it’s very important to note that there are cost problems in the Part D program we have to address,” Cavanaugh said.
In 2015, there was an 11.6% growth in the cost per beneficiary in the Part D program, and in 2016, the cost will go up by more than 10% for 2 years in a row of double-digit growth.
Part D is one of the fastest growing parts of the Medicare program, and Cavanaugh acknowledged that the rising cost of prescription drugs is not unique to Medicare. It does raise a lot of questions that need answers, such as what the rising cost of Part D means for MA and what tools CMS has to constrain the costs so beneficiaries continue to have access to these drugs.
So what does the future of MA hold? Multiple forecasts from a variety of agencies and organizations do predict that enrollment and penetration of MA plans will plateau in a few years. CMS has been considering why that might be, and that means understanding why some beneficiaries choose MA to begin with and why others make the conscious decision not to enroll in MA.
In the future, CMS will have to gain a better handle on management of the catastrophic coverage part of Part D. Once enrollees reach catastrophic coverage, Medicare pays the majority of their drug costs. Cavanaugh showed that from 2010 to 2014, the catastrophic benefit became more and more prominent. While the numbers for 2015 and 2016 are not finalized and, therefore, haven’t officially been released, he did note that the number of beneficiaries reaching the catastrophic coverage benefit has grown dramatically.
“The government is bearing most of the risk [for catastrophic coverage],” Cavanaugh said. “How do we get better management of the catastrophic part?”
One idea is to shift more and more cost to the Part D plans, but that’s not the sole answer to the issue.
Ultimately, while MA has been very successful, there are a number of major concerns to think about for the future of MA and the Part D plan, Cavanaugh said.
“Things have never been better, and the challenges have never been greater,” he said.
AI in Health Care: Balancing Governance, Innovation, and Trust
September 2nd 2025In this conversation with Reuben Daniel, associate vice president of artificial intelligence at UPMC Health Plan, we dive into how UPMC Health Plan builds trust with providers and members, discuss challenges of scaling AI effectively, and hear about concrete examples of AI's positive impact.
Listen
Health Care Utilization and Cost of Diagnostic Testing for Respiratory Infections
September 17th 2025Syndromic reverse transcriptase–polymerase chain reaction tests for respiratory infections were associated with lower health care resource utilization and costs, implicating potential for improved value in patient care.
Read More
Infertility Coverage Boosts ART Use and Pregnancy Success: Richard A. Brook, MS, MBA
August 26th 2025In this episode, Richard A. Brook, MS, MBA, discusses his study showing that infertility treatment coverage increases assisted reproductive technology (ART) use and improves pregnancy outcomes.
Listen
ACA Network Regulatory Filings Are Inaccurate, Poorly Match Provider Directories
September 16th 2025A secret shopper survey (N = 8306) in Pennsylvania’s Affordable Care Act (ACA) Marketplace found inconsistencies between carrier regulatory filings and provider directories, frequent inaccuracies in regulatory filings, and challenges in securing timely appointments.
Read More
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD
September 15th 2025The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Read More